hide
Free keywords:
Glycoconjugate, Targeted delivery, Glucose transporter, Anticancer drugs
Abstract:
First observed in 1920s, the Warburg effects have inspired scientists to harness the unique glucose metabolism of cancer cells for targeted therapy for a century. Carbohydrate-drug conjugates are explicitly designed for selective uptake by cancer cells overexpressing glucose transporters. We summarize the progress in developing glycoconjugates for cancer-specific targeting and treatment over the past decade (2010–2020) and point to some future directions in this field.